Table 2.
18F-florbetapir SUVRs in the healthy controls (HCs) and patients with major depressive disorder (MDD) with differing levels of treatment resistance in seven cortical VOIs and the global cortex
| Region | HCs | MDD patients | P value | |
|---|---|---|---|---|
| Mild treatment resistance | Moderate-to-severe treatment resistance | |||
| Frontal | 0.365 | |||
| Mean ± SD | 1.09 ± 0.09 | 1.12 ± 0.11 | 1.11 ± 0.15 | |
| Median (IQR) | 1.07 (1.04–1.16) | 1.09 (1.06–1.15) | 1.07 (1.03–1.15) | |
| Anterior cingulate | 0.606 | |||
| Mean ± SD | 1.21 ± 0.11 | 1.24 ± 0.12 | 1.21 ± 0.15 | |
| Median (IQR) | 1.18 (1.13–1.30) | 1.24 (1.16–1.33) | 1.22 (1.11–1.29) | |
| Posterior cingulate | 0.251 | |||
| Mean ± SD | 1.31 ± 0.12 | 1.31 ± 0.16 | 1.36 ± 0.16 | |
| Median (IQR) | 1.28 (1.21–1.43) | 1.29 (1.24–1.41) | 1.35 (1.27–1.44) | |
| Occipital | 0.284 | |||
| Mean ± SD | 1.15 ± 0.08 | 1.18 ± 0.08 | 1.21 ± 0.13 | |
| Median (IQR) | 1.16 (1.09–1.21) | 1.17 (1.14–1.23) | 1.19 (1.12–1.24) | |
| Parietal | 0.032* | |||
| Mean ± SD | 1.01 ± 0.08 | 1.08 ± 0.11 | 1.11 ± 0.15a* | |
| Median (IQR) | 1.03 (0.94–1.06) | 1.06 (1.00–1.17) | 1.08 (1.02–1.14) | |
| Precuneous | 0.201 | |||
| Mean ± SD | 1.02 ± 0.08 | 1.06 ± 0.1 | 1.10 ± 0.17 | |
| Median (IQR) | 1.02 (0.95–1.09) | 1.04 (1.00–1.10) | 1.06 (0.99–1.13) | |
| Temporal | 0.693 | |||
| Mean ± SD | 1.03 ± 0.06 | 1.02 ± 0.07 | 1.03 ± 0.12 | |
| Median (IQR) | 1.02 (1.00–1.07) | 1.01 (0.99–1.04) | 1.00 (0.95–1.08) | |
| Global | 0.52 | |||
| Mean ± SD | 1.13 ± 0.07 | 1.15 ± 0.09 | 1.16 ± 0.13 | |
| Median (IQR) | 1.11 (1.07–1.16) | 1.13 (1.11–1.19) | 1.14 (1.09–1.18) | |
aSignificant difference as compared with HCs: *P < 0.05